Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics ($AKBA) is expected to see a move up heading into Q3 earnings report, with analysts predicting a healthy increase in scripts. The stock has been upgraded to HOLD AND ACCUMULATE, with industry analysts giving a median price target of $6.25 and a high target of $8.00. The company's revenue trend is positive, and earnings are expected to grow significantly. Despite aggressive price manipulation, AKBA's performance has been strong, with all industry analysts recommending a "BUY" rating. Major catalysts are expected in the coming quarters, including DaVita opening access to V for all patients.